참고문헌
- Parkin, D.M., Pisani, P. & Ferlay, J. Global cancer statistics. CA Cancer J Clin. 49, 33-64 (1999). https://doi.org/10.3322/canjclin.49.1.33
- Schafer, D.F. & Sorrell, M.F. Hepatocellular carcinoma. Lancet 353, 1253-1257 (1999) https://doi.org/10.1016/S0140-6736(98)09148-X
- de La Coste, A. et al. Somatic mutations of the betacatenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 95, 8847-8851 (1998)
- Satoh, S. et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet. 24, 245-250 (2000) https://doi.org/10.1038/73448
- Fearon, E.R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759-767 (1990) https://doi.org/10.1016/0092-8674(90)90186-I
- Kinzler, K.W. & Vogelstein, B. Life (and death) in a malignant tumour. Nature 379, 19-20 (1996) https://doi.org/10.1038/379019a0
- Pang, A., Ng, I.O., Fan, S.T. & Kwong, Y.L. Clinicopathologic significance of genetic alterations in hepatocellular carcinoma. Cancer Genet Cytogenet 146, 8-15 (2003) https://doi.org/10.1016/S0165-4608(03)00103-1
- Marks, P.A., Richon, V.M. & Rifkind, R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst. 92, 1210-1216 (2000) https://doi.org/10.1093/jnci/92.15.1210
- Weidle, U.H. & Grossmann, A. Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment. Anticancer Res. 20, 1471-1485 (2000)
- Frye, R.A. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun. 273, 793-798 (2000) https://doi.org/10.1006/bbrc.2000.3000
- Imai, S., Armstrong, C.M., Kaeberlein, M. & Guarente, L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403, 795-800 (2000) https://doi.org/10.1038/35001622
- Yang, W.M. et al. Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family. J Biol Chem. 272, 28001-28007 (1997) https://doi.org/10.1074/jbc.272.44.28001
- Ballestar, E. & Esteller, M. The impact of chromatin in human cancer: linking DNA methylation to gene silencing. Carcinogenesis 23, 1103-1109 (2002) https://doi.org/10.1093/carcin/23.7.1103
- Gui, C.Y. et al. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter- associated proteins, including HDAC1. Proc Natl Acad Sci USA 101, 1241-1246 Epub 2004 Jan 20 (2004)
- Villar-Garea, A. & Esteller, M. Histone deacetylase inhibitors: Understanding a new wave of anticancer agents. Int J Cancer 112, 171-178 (2004) https://doi.org/10.1002/ijc.20372
- Zhu, P. et al. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5, 455-463(2004) https://doi.org/10.1016/S1535-6108(04)00114-X
- Clements, W.M. et al. Beta-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. Cancer Res. 62, 3503-3506 (2002)
- Park, W.S. et al. Somatic mutations of the trefoil factor family 1 gene in gastric cancer. Gastroenterology 119, 691-698 (2000) https://doi.org/10.1053/gast.2000.16483
- Park, W.S. et al. Inactivating mutations of the caspase- 10 gene in gastric cancer. Oncogene 21, 2919- 2925 (2002) https://doi.org/10.1038/sj.onc.1205394